Table 1 Baseline characteristics of patients in the two cohorts
Variables | Chinese cohort (N = 949) | Swedish cohort (N = 1639) | P-value |
|---|---|---|---|
Demographics | Â | Â | Â |
Age, years | Â | Â | Â |
 Mean (SD) | 61.6 ± 15.0 | 76.4 ± 13.4 | < 0.001 |
 Median (IQR) | 64 (52–73) | 79 (69–86) | < 0.001 |
Female, n (%) | 442 (46.6) | 677 (41.6) | 0.013 |
Clinical history, n (%) | Â | Â | Â |
Ischemic heart disease | 182 (19.2) | 524 (32.0) | < 0.001 |
Dilated cardiomyopathy | 245 (25.8) | 116 (7.1) | < 0.001 |
Hypertension | 349 (36.8) | 1050 (64.2) | < 0.001 |
Valvular disease | 300 (31.6) | 671 (40.9) | < 0.001 |
Atrial fibrillation/flutter | 376 (39.6) | 905 (55.3) | < 0.001 |
Diabetes mellitus | 295 (31.1) | 465 (28.4) | 0.144 |
Pulmonary disease | 118 (12.4) | 352 (21.5) | < 0.001 |
Anemia | 359 (37.9) | 708 (43.5) | 0.005 |
Physical/laboratory | Â | Â | Â |
SBP, mmHg | 114.2 ± 15.4 | 126.1 ± 20.3 | < 0.001 |
DBP, mmHg | 69.1 ± 10.1 | 71.7 ± 11.3 | < 0.001 |
Heart rate, beats/min | 83.7 ± 20.9 | 72.2 ± 14.3 | < 0.001 |
Hemoglobin, g/L | 129.3 ± 23.9 | 127.8 ± 18.0 | 0.002 |
eGFR, ml/min/1.73m2 | 63.5 ± 32.4 | 61.6 ± 35.8 | 0.002 |
NT-proBNP, | 3251 | 4540 | 0.013 |
Median (IQR), pg/mL | (1469–7602) | (1750–9475) |  |
LVEF, %, n (%) | Â | Â | 0.084 |
 ≥ 40 | 562 (59.4) | 916 (55.9) |  |
 < 40 | 387 (40.8) | 723 (44.1) |  |
QRS duration, ms, n (%) |  |  | < 0.001 |
 ≥ 120 | 288 (30.3) | 605 (36.9) |  |
 < 120 | 661 (69.7) | 1034 (63.1) |  |
LBBB, n (%) | 174 (18.4) | 148 (10.0) | < 0.001 |
Medication, n (%) | Â | Â | Â |
ACEIs/ARBs | 463 (48.8) | 1324 (80.8) | < 0.001 |
Beta-blockers | 558 (58.8) | 1417 (86.5) | < 0.001 |
Aldosterone antagonists | 632 (66.6) | 502 (30.6) | < 0.001 |
Diuretics | 724 (76.3) | 1232 (75.2) | 0.522 |
Digitalis | 379 (39.9) | 215 (13.1) | < 0.001 |
Device therapy, n (%) | Â | Â | Â |
Pacemaker | 47 (5.0) | 193 (11.8) | < 0.001 |
CRT-P/D | 57 (6.0) | 35 (2.1) | < 0.001 |
ICD | 44 (4.6) | 24 (1.5) | < 0.001 |